Myrtle S Potter
CIK 1214130 · last filed 2026-06-23
Myrtle S Potter is a corporate insider who has filed 109 SEC Form 4 insider transactions across 16 companies since 2007. The most recent filing shows the insider sold $204.1K of GH on Jun 23, 2026. Across all open-market trades the lifetime net is −$2.5M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $40.4M across reported positions. 7 SEC filings were submitted jointly with AMAZON COM INC. 7 Form 144 notices of planned sales are also on file; the latest, for GH on Jun 22, 2026, lists the filer as a director.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ESRX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
PALO ALTO, CA 94304
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| GH | Director | 20,971 | $146.61 | $3.07M | -$341.9K | 46 | 2026-06-23 |
| DNA | Director | 10,822 | $8.29 | $89.8K | $0 | 1 | 2025-06-13 |
| Ginkgo Bioworks Holdings, Inc. (DNA.WS) Delisted | Director | — | $0.01 | — | $0 | 1 | 2024-06-14 |
| Myovant Sciences Ltd. (MYOV) Delisted | Director | 0 | $26.98 | $0 | $0 | 6 | 2023-03-10 |
| Urovant Sciences Ltd. (UROV) Delisted | Director | 21,480 | $16.24 | $348.8K | $0 | 4 | 2020-07-23 |
| Immunovant, Inc. (IMVTW) Delisted | Director | — | — | — | $0 | 1 | 2019-12-20 |
| ABUS | Director | — | $4.08 | — | $0 | 2 | 2019-08-20 |
| AXSM | Director | — | $135.63 | — | $0 | 3 | 2019-06-10 |
| INSM | Director | 25,510 | $144.65 | $3.69M | -$82.7K | 7 | 2018-05-17 |
| RITE AID CORP (RAD) Delisted | Director | 3,940 | $0.65 | $2.6K | -$58.9K | 5 | 2017-10-05 |
| Everyday Health, Inc. (EVDY) Delisted | Director | 0 | — | — | -$727.0K | 4 | 2016-12-06 |
| Express Scripts Holding Co. (ESRX) Delisted | Director | 8,774 | — | — | -$839.4K | 3 | 2012-06-01 |
| MEDCO HEALTH SOLUTIONS INC (MHS) Delisted | Director | 0 | — | — | $0 | 6 | 2012-04-03 |
| AMZN | Director | 130,000 | $257.74 | $33.51M | -$458.2K | 4 | 2009-04-13 |
| ev3 Inc. (EVVV) Delisted | Director | 1,921 | — | — | $0 | 1 | 2007-10-09 |
| FOXHOLLOW TECHNOLOGIES, INC. (FOXH) Delisted | Director | 1,186 | — | — | $0 | 4 | 2007-09-05 |
Recent Filings
109 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-23 | GH | Sell (S)10b5-1 | −1,556 | -$204.1K | EDGAR |
| 2026-06-22 | GH | Notice (144) Director · Planned Jun 22, 2026 · 10b5-1 plan Sold: Form 4 filed Jun 23, 2026 |
−1,556 | -$204.1K | EDGAR |
| 2026-06-22 | GH | Mixed | +4,203 | $0 | EDGAR |
| 2025-10-20 | GH | Sell (S)10b5-1 | −26 | -$1.7K | EDGAR |
| 2025-10-17 | GH | Notice (144) Director · Planned Oct 17, 2025 · 10b5-1 plan Sold: Form 4 filed Oct 20, 2025 |
−26 | -$1.7K | EDGAR |
| 2025-10-16 | GH | Exer (M) | +69 | $0 | EDGAR |
| 2025-09-17 | GH | Notice (144) Director · Planned Sep 17, 2025 · 10b5-1 plan Sold: Form 4 filed Sep 17, 2025 |
−26 | -$1.4K | EDGAR |
| 2025-09-17 | GH | Mixed10b5-1 | +42 | -$1.4K | EDGAR |
| 2025-08-20 | GH | Sell (S)10b5-1 | −26 | -$1.5K | EDGAR |
| 2025-08-19 | GH | Notice (144) Director · Planned Aug 19, 2025 · 10b5-1 plan Sold: Form 4 filed Aug 20, 2025 |
−26 | -$1.5K | EDGAR |
10b5-1: the filer ticked the box for trades made under a Rule 10b5-1 trading plan, which sets the sales (or buys) in advance, so they say less about the insider's view at the time than a discretionary trade. The plan's adoption date is shown when the filing's footnotes give it.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment, and an amended or cancelled notice is not listed. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes. Someone who is no longer an officer or director (or never was) files no Form 4, so for them a sale shows up only on a later notice, which lists the seller's sales from the 3 months before it. "No sale on file" means neither record shows one; a dash in Net $ means the value filed on the notice doesn't fit the stock's price (likely a typo).